UMIN-CTR Clinical Trial

Basic information
Public title	The 2nd Matsue City Pancreatic Cancer Project
Acronym	The 2nd Matsue City Pancreatic Cancer Project
Scientific Title	The 2nd Matsue City Pancreatic Cancer Project
Scientific Title:Acronym	The 2nd Matsue City Pancreatic Cancer Project
Region	Japan

Condition
Condition	Pancreatic tumor
Classification by specialty	Hepato-biliary-pancreatic medicine
Classification by malignancy	Malignancy
Genomic information	NO

Objectives
Narrative objectives1	We verify the frequency of pancreatic cancer detection through collaboration between practitioners and general hospital doctors.
Basic objectives2	Others
Basic objectives -Others	a prospective observational study
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	Blood tests, abdominal ultrasonography, MRI, computed tomography, endoscopic ultrasonography will be performed on symptomatic patients to confirm the frequency of pancreatic cancer detection.
Key secondary outcomes

Base
Study type	Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	40 years-old <=
Age-upper limit	120 years-old >
Gender	Male and Female
Key inclusion criteria	Patients suspected of having pancreatic cancer due to clinical symptoms Patients with multiple risk factors for pancreatic cancer Patients whose clinical course cannot deny pancreatic cancer
Key exclusion criteria	none
Target sample size	300

Research contact person
Name of lead principal investigator	1st name Kazuya Middle name Last name Matsumoto
Organization	Medical corporation Irisawa Medical Clinic
Division name	Internal Medicine
Zip code	690-0025
Address	285-6, Yawata-cho, Matsue 690-0025
TEL	0852-38-8211
Email	matsumotokazuya@tottori-u.ac.jp

Public contact
Name of contact person	1st name Kazuya Middle name Last name Matsumoto
Organization	Medical corporation Irisawa Medical Clinic
Division name	Internal Medicine
Zip code	690-0025
Address	285-6, Yawata-cho, Matsue 690-0025
TEL	0852-38-8211
Homepage URL
Email	matsumotokazuya@tottori-u.ac.jp

Sponsor
Institute	Matsue Medical Association
Institute
Department

Funding Source
Organization	none
Organization
Division
Category of Funding Organization	Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization	Matsue Red Cross Hospital
Address	200, Horo-cho, Matsue, 690-0086
Tel	0852-24-2111
Email	kushiyama_yoshinori@matsue.jrc.or.jp

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2022 Year 05 Month 25 Day

Related information
URL releasing protocol
Publication of results	Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status	Enrolling by invitation
Date of protocol fixation	2022 Year 01 Month 06 Day
Date of IRB	2022 Year 03 Month 31 Day
Anticipated trial start date	2022 Year 06 Month 01 Day
Last follow-up date	2027 Year 05 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information	If abdominal ultrasonography reveals dilated main pancreatic duct, pancreatic cyst, or pancreatic tumor lesion, blood test reveals abnormalities, or if pancreatic cancer cannot be ruled out from the clinical course, refer to a detailed examination medical institution. Cases that have undergone a further examination will be registered in the "2nd Matsue City Pancreatic Cancer Project".

Management information
Registered date	2022 Year 05 Month 19 Day
Last modified on	2022 Year 05 Month 19 Day

Link to view the page
URL(English)	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054490